Tempus AI’s $1.5 billion purchase of Personalis triggers a sell-off in shares of both companies despite strategic interest in cancer diagnostics.
Tempus AI agreed to acquire cancer diagnostics firm Personalis for $1.5 billion, aiming to bolster its portfolio in tumor DNA screening technology. The deal follows reports that Merck and other suitors had expressed interest in Personalis, which specializes in blood tests detecting circulating tumor DNA.
Personalis shares had surged last week on takeover speculation, but the formal announcement led to a sharp decline for both companies. Tempus AI, which went public earlier this year, has been expanding its precision medicine capabilities, while Personalis has faced challenges scaling its commercial operations.
Shares of Tempus AI (TEM) and Personalis (PSNL) fell in early trading, reflecting investor concerns over valuation and integration risks despite the deal’s long-term strategic potential.